Ann: Phase II study for indication expansion of TLX250-CDx doses, page-5

Dr Colin Hayward, Telix Chief Medical Officer, said, “Building on the success of ZIRCON and positive
preliminary results in investigator-initiated studies of TLX250-CDx in bladder and breast cancer,
4 dosing a first patient in the STARBURST study is a strategically important milestone for Telix. This
study will add value and clinical insight to the platform and enable Telix to assess the potential of
CAIX as a biomarker as we continue to scout the theranostic potential of targeting CAIX beyond
renal cancer. We would like to thank Dr Kiser and his clinical team at Carilion Clinic, as well as the
patients who will contribute to the study.”

Another positive step for Telix.